Antibody Drug Conjugates for Cancer Therapy

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Antibody drug conjugates (ADCs) are an emerging class of cancer therapeutics.
• ADCs leverage antibodies to target cancer cells expressing specific antigens.
• A cytotoxic drug is conjugated to the antibody via a linker for targeted delivery.

Purpose of the Study:

• To review antibody drug conjugates (ADCs) that have progressed to clinical investigation.
• To emphasize the influence of targets, linker chemistries, and drugs on ADC behavior.
• To provide an overview of the current landscape of ADC therapeutics in clinical trials.

Main Methods:

• Literature review of clinical-stage ADCs.
• Analysis of ADC components: antibody targets, linker technologies, and cytotoxic payloads.
• Focus on ADCs with advanced clinical evaluation.

Main Results:

• Over 40 distinct ADCs are currently in clinical evaluation.
• Diverse antigens, drugs, and linker chemistries are employed in ADC development.
• The interplay between target antigen, linker, and drug significantly affects ADC performance.

Conclusions:

• Antibody drug conjugates represent a promising strategy in cancer therapy.
• Understanding the specific attributes of each ADC is crucial for optimizing treatment.
• Continued clinical investigation will further elucidate the potential of ADC technology.